Long only, biotech

With Recent Trial Results, Furiex Pharmaceuticals Still Has Significant Upside Potential

I had never heard of Furiex Pharmaceuticals (NASDAQ:FURX) before Tuesday. Despite having two approved drugs, and a third in phase III clinical trials, the company flew largely under the biotech radar. However, it was hard to miss the news Tuesday when positive results in their phase III trials in diarrhea-predominant irritable bowel syndrome (IBS-d) sent the stock from $46 to over $118 in the first minutes of trading.

Clearly, something had gone very well for Furiex, but with the price moving so quickly there wasn't much time to analyze the situation. Luckily, the company and its pipeline are fairly small and simple so due diligence was relatively easy. Eluxadoline, the IBS-d drug which just completed the phase III...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details